| Clinical data | |
|---|---|
| Other names | Pentarane B; 6α-Methyl-16α,17α-cyclohexanoprogesterone |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H38O2 |
| Molar mass | 382.588 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mecigestone, also known as pentarane B, as well as 6α-methyl-16α,17α-cyclohexanoprogesterone, 6α-methylcyclohexano[1',2';16,17]pregn-4-ene-3,20-dione, or 17α-acetyl-6α-methyl-16β,24-cyclo-21-norchol-4-en-3-one, is a steroidal progestin that was developed by the Zelinskii Institute of Organic Chemistry of the Russian Academy of Sciences and has been proposed for clinical use as a progestogen but has not been marketed.[1][2][3][4][5] It is the 6α-methylated analogue of pentarane A, which is also known as D'6-pentarane or pregna-D'6-pentarane.[5]
Synthesis
[edit]The synthesis has been reported:[6] Patent:[7] Precursor:[8] Micronization technology:[9]

- The Diels-Alder reaction of 16-DPA [979-02-2] (1) with butadiene gives PC99565806 (2). It is important to recognize that for mecigestone the stereochemistry about the E-ring is cis and not trans. The trans isomer is PC99565808.
- Ex 1: Epoxidation of the olefin with ethereal Monoperphthalic acid [2311-91-3] occurs to give (3). A search of the pubchem registry only gave the trans configuration about the E-ring (PC11873237), and not the expected cis stereochemistry.
- The reaction with methyl magnesium iodide occurs with a regioselectivity to the 6 position from the beta face. Saponification of the acetate ester also occurs during the work-up to give (4).
- The Jones oxidation leads to the enone of the finished product. Epimerization of the beta-methyl group also occurred during this step. Thus, completing the synthesis of mecigestone (5).
See also
[edit]References
[edit]- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 8–. ISBN 978-1-4757-2085-3.
- ^ Fedyushkina IV, Skvortsov VS, Romero Reyes IV, Levina IS (2014). "Molecular docking and 3D-QSAR of 16α,17α-cycloalkanoprogesterone derivatives as ligands of the progesterone receptor". Biochemistry (Moscow) Supplement Series B. 8 (2): 168–176. doi:10.1134/S1990750814020048. ISSN 1990-7508. S2CID 96191380.
- ^ Kamernitzky AV, Levina IS, Kulikova LE, Ignatov VN, Korkhov VV, Nikitina GV, Terekhina AI (January 1982). "Pregna-D'-pentaranes - a new class of active gestagenes". Journal of Steroid Biochemistry. 16 (1): 61–67. doi:10.1016/0022-4731(82)90144-3. PMID 7062740.
- ^ Nazarov AK, Zavarzin IV, Nazarov GV, Aksenov AV, Levina IS (2016). "Preparation and Bioavailability Evaluation of Micronized Steroidal Mecigestone Drug Substance". Pharmaceutical Chemistry Journal. 49 (10): 706–710. doi:10.1007/s11094-016-1357-6. ISSN 0091-150X. S2CID 6216213.
- ^ a b Bhakta A, Herman M, Levina IS, Moudgil VK (August 1993). "Interaction of cycloalkanoprogesterones with mammalian progesterone receptor: binding of pregna-D'-pentaranes in the calf uterine cytosol". Molecular and Cellular Biochemistry. 125 (2): 153–161. doi:10.1007/BF00936444. PMID 8283970. S2CID 20319611.
- ^ Kamernitskii, A. V., Kulikova, L. E., Levina, I. S., Korkhov, V. V., Nikitina, G. V. (September 1980). "Biological activity of transformed steroids XV. Synthesis and hormonal activity of 6-methyl-substituted 16α, 17α-cyclohexanoprogesterones". Pharmaceutical Chemistry Journal. 14 (9): 632–635. doi:10.1007/BF01156378.
- ^ , GB1427645 (1976 to Inst Orch Khim); CA, 85, 21727
- ^ Nazarov, A. K., Sigay, N. V., Zavarzin, I. V., Levina, I. S. (September 2014). "Synthesis of 6-methylidene-16α,17α-cyclohexapregn-4-ene-3,20-dione". Russian Chemical Bulletin. 63 (9): 2064–2066. doi:10.1007/s11172-014-0701-9.
- ^ Nazarov, A. K., Zavarzin, I. V., Nazarov, G. V., Aksenov, A. V., Levina, I. S. (January 2016). "Preparation and Bioavailability Evaluation of Micronized Steroidal Mecigestone Drug Substance". Pharmaceutical Chemistry Journal. 49 (10): 706–710. doi:10.1007/s11094-016-1357-6.